Drug intelligence / Profile preview

Femmican

Development stage: Preclinical
Lead developer: Bazelet Technologies
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Sublingual

Overview

**Femmican** is Bazelet's branded range of standardized, terpene-enriched medical cannabis oils designed around reported sex-related differences in cannabis metabolism. The range includes multiple THC/CBD compositions, including T1/C20, T3/C15, and T10/C10, with indica and sativa terpene profiles in MCT oil for sublingual administration. It is intended for women's health, but no single disease indication, individual terpene composition, or formulation-specific molecular mechanism has been publicly disclosed for the overall Femmican brand range. ([bazelet-tech.com](https://bazelet-tech.com/products.html))

Brand names: Femmican

Beyond the preview

Go deeper on Femmican.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Femmican.

Explore the full profile